Products
Englumafusp Biosimilar Fusion Protein (CD19) for Research
Cat No.: GMP-Bios-INN-1182
Anti-CD19 therapeutic antibody (Pre-made Englumafusp biosimilar,Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Englumafusp (development code RG-6076) is a fusion protein targeting CD19. It is developed by Roche for B cell lymphoma. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1182-1mg | 1mg | 3090 |
| GMP-Bios-INN-1182-10mg | 10mg | |
| GMP-Bios-INN-1182-100mg | 100mg | |
| GMP-Bios-INN-1182-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Englumafusp biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting CD19/B-lymphocyte antigen CD19/B-lymphocyte surface antigen B4/Differentiation antigen CD19 |
| INN Name | Englumafusp |
| Target | CD19 |
| Format | Fusion Protein |
| Derivation | na |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2021 |
| Year Recommended | 2022 |
| Companies | Roche |
| Conditions Approved | na |
| Conditions Active | B cell Lymphoma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
